Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56,260,480
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
8,974,632
-
Shares change
-
+1,296,324
-
Total reported value, excl. options
-
$13,507,225
-
Value change
-
+$1,945,492
-
Put/Call ratio
-
2.4%
-
Number of buys
-
11
-
Number of sells
-
18
-
Price
-
$1.50
Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q2 2023
52 filings reported holding QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share as of 30 Jun 2023.
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) had 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 8,974,632 shares of stock of the company.
Largest 10 holders included TANG CAPITAL MANAGEMENT LLC, BML Capital Management, LLC, EPIQ Capital Group, LLC, VANGUARD GROUP INC, BlackRock Inc., RENAISSANCE TECHNOLOGIES LLC, KNIGHTSBRIDGE ASSET MANAGEMENT, LLC, TWO SIGMA ADVISERS, LP, Alphabet Inc., and GEODE CAPITAL MANAGEMENT, LLC.
This table shows the top 38 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.